Investorideas.com - Cannabis Deal Tracker: Investment and M&Amp;Amp;Amp;A Activity in the Cannabis Industry July 27th - July 31st, 2020
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Wednesday 5 August 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 450 (CSE: $CXXI.C) (NASDAQ: $VFF) (TSXV: $RLV.V) (TSXV: $WMD.V)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 450 (CSE: $CXXI.C) (NASDAQ: $VFF) (TSXV: $RLV.V) (TSXV: $WMD.V)
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/080520-StocksToWatch.mp3
Read this in full
at http://www.investorideas.com/news/2020/cannabis-potcasts/08051CXX-VFF-RLV-WMD.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on
Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public company announcements.
C21
Investments Inc. (CSE: CXXI) (OTCQB: CXXIF) announced record revenue at its Nevada
dispensaries for its second quarter ("Q2" ending July 31, 2020) as
well as for the month of July 2020.
Nevada
Retail Highlights:
● Q2
retail revenue sets record for a quarter, surpassing the previous high in Q3 of
last year
● July
sets a monthly revenue record; first month over $3 million at Silver State
dispensaries and best month ever at the Fernley dispensary
● $98.5k
retail revenue run rate per day in July; previous record of $96.5k in June 2020
● $63
average ticket size in Q2
● Phantom Farms
flower continues as Silver State's top SKU – 13 of the top 25 SKUs are the
Company's Oregon brands
Company CEO and President, Sonny
Newman: "We are very pleased with the record Q2 and July performance at
our Nevada dispensaries which is a testament to the dedication of our team. We
are proud to be celebrating our fifth anniversary as Nevada's first licensed
dispensary. Despite beginning the quarter under state-mandated delivery-only
sales, we responded quickly and began operating three complementary sales
channels in May as restrictions eased. Our strong and loyal customer base
continues to mitigate the impact of the pandemic on our Nevada business. While
both dispensaries are performing exceptionally well, our Fernley dispensary
continues to significantly exceed expectations with July recording its best
month of sales to date."
"In the second quarter C21 has
continued to optimize its Oregon operations. As of June, several non-core
Oregon assets are subject to third-party management agreements and nearing the
completion of sale, which will generate cash, and reduce costs and liabilities
from mid-June onwards. With operations streamlined in Oregon, and robust
revenue and EBITDA margins at our Silver State dispensaries, C21 is working to
deepen its presence in Nevada as we continue to make progress in establishing
our debt facility."
"As reported in our recent
year-end financials, our Nevada dispensaries generated an average of
approximately $16 million in revenue and $6 million in adjusted EBITDA per dispensary.
With the ability to replicate and scale both our profitable dispensary model,
and our vertically integrated operations in Nevada, and with 80% of our
cultivation and production facility still untapped, we expect to build on Q2's
record retail revenue and enhance shareholder value moving forward," said
Mr. Newman.
Village
Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) announced that it has executed a binding
agreement to acquire 6.6% of Australia-based Altum International Pty Ltd, one
of the Asia-Pacific's leading cannabinoid platforms, subject to the completion
of certain conditions, which are expected to be finalized in the next several
weeks. Under the terms of the Agreement,
Village Farms has the option to increase its ownership in Altum on similar
terms.
Altum's mission is to bring the
life-changing benefits of cannabinoids (with focus on CBD) to consumers across
the Asia-Pacific region through a comprehensive platform for the large-scale
importation, distribution and marketing of CBD, composed of three channels,
with an overriding focus on regulatory compliance for each specific country
market:
● Proprietary
Consumer Brands – Fully-owned consumer brands, currently consisting of Felix and Co (www.felixandco.com), Kind Cannabis and tsubomi;
● Commercial
Inputs – A range of cost-competitive, compliant and effective premium CBD
ingredients through its LIFE brand
(www.lifecbd.asia), designed for seamless addition to foods, beverages,
cosmetics and other consumer packaged goods; and,
● Retail –
Retail sales and educational and experiential stores for both Altum and partner
products.
●
Altum has initially focused on
opportunities in Hong Kong, which has one of the most progressive attitudes and
regulatory regimes for CBD in the Asia-Pacific region. It has already launched a broad range of CBD
products under its Felix and Co brand
to very favorable customer feedback and strong initial sales traction. In its Commercial Input channel, Altum is
supplying craft brewers for CBD-infused beer, as well as market-wide coffee
chains and juice bars for beverages and edibles, and is in advanced discussions
for supply agreements to provide inputs for a range of other products,
including pet food, cosmetics, and spa products for hotels. In June 2020, Altum opened a boutique café
and retail concept store in Hong Kong named Found
– Asia's first dedicated CBD consumer outlet. Altum plans to pursue its
business strategy throughout the Asia-Pacific region, including but not limited
to Greater China, Japan, South Korea, Thailand, Australia and New Zealand, with
the goal to be commercially active in at least three additional countries in
the next 12 months.
Altum is also pursuing high-THC
medical cannabis opportunities in Australia and New Zealand, where medicinal
cannabis is already legal in both countries, and intends to pursue recreational
cannabis opportunities in each of those countries should legalization
occur. Altum is well positioned to
capitalise on the medicinal cannabis opportunity in New Zealand via a 49%
interest in Kariki Pharma Limited (www.karikipharma.com). Kariki is a New
Zealand-domiciled medicinal cannabis company focused on creating a suite of
pharmaceutical quality medicinal cannabis for New Zealand, Australian, Asian,
and European patients and export markets.
New Zealand intends to hold a national referendum on the legalization of
the recreational use of cannabis on 19 September 2020.
"On the heels of our recent
investment in the Netherlands, our partnership with Altum represents another
meaningful step to leverage our three decades of experience in vertically
integrated, intensive agriculture, as well as our cannabis success in Canada,
for international CBD and cannabis opportunities," said Michael DeGiglio,
CEO, Village Farms International. "Village Farms is at a place where, with
well-established North American operations, continuously refined and enhanced
for optimized performance and growth, we are able to turn our attention to
strategic, early-stage international opportunities where CBD and cannabis are
being legalized in our pursuit of well-researched capital allocation for the
generation of outsized, long-term returns."
"With approximately 4.5 billion
people – more than four times that of the U.S., Canada and Europe combined –
the Asia-Pacific market represents one such sizeable but nascent opportunity,
with the addressable market for cannabis alone forecast to reach US$10 billion
by 2024. Altum is an outstanding
organization at the very forefront of the emerging CBD industry in the
Asia-Pacific region and represents a capital efficient means by which to
participate in this significant opportunity, as well as the legal medical, and
potentially the legal recreational, cannabis markets in Australia and New
Zealand."
Relevium
Technologies Inc. (TSXV: RLV) (OTC: RLLVF) announced that it has secured licenced a
patented science based nutraceutical formulation that addresses major points of
viral invasion, replication and toxicities develop by Dr. Dana F. Flavin, an
internationally-recognized expert in immune modulation and the prevention and
treatment of viruses and cancer.
The patented formulation developed
by Dr. Dana F. Flavin, which will be marketed under the Company’s Bioganix
brand, was developed to work with multiple pathways to combat viral infections,
including COVID-19, by increasing the antiviral defense while decreasing the
replication and toxicity of the virus.
According to Dr. Dana Flavin, the
most important aspect of a multiple pathway approach is synergy – a process in
which some substances cooperate to reach a combined effect that is greater than
the sum of their separate effect. Synergy is not only important in the
development of a specific effective formulation, but also as an adjunct to
conventional drug therapy.
The patented formulation was
designed the address viral infections through a synergistic interaction of
several natural and GRAS ingredients that amplify effect of ingredients working
with enhanced supportive mechanisms, which show greater efficacies based on
their expansion of the biochemical processes and pharmacological activities.
Based on research about specific
ingredients, the following natural substances offer important benefits in the
prevention and treatment of viral infection such as COVID-19. When combined,
their qualities are amplified for effectiveness.
N-acetylcysteine
(NAC)
added for its ability proven in clinical studies to increase lymphocytes that
contain interferon. Lymphocytes are often suppressed in viral infections like
COVID-19. These cells that release interferon are part of the Th1 lymphocytes
important for their antiviral activity. One of the mechanisms in this
lymphocyte suppression is the generation of a gas, nitric oxide. This gas comes
from an enzyme, nitric oxide synthase, and is elevated in viral infections. NAC
binds to this gas and allows the movement of these lymphocytes back into the
blood stream and an increased antiviral activity of these Th1 lymphocytes.
Additionally, NAC increases the endogenous anti-inflammatory factor,
glutathione, in the lung tissue.
Olive
Leaf Extract and Licorice Root added for their ability proven in
clinical studies to increase the release of interferon. One of the most
important mechanisms in viral defense is to increase interferon, which works
directly against virus replication and/or invasion. Many natural substances
increase the release of interferon. Combined, olive leaf extract and licorice
root are the most effective natural substances to increase this release of
interferon from the lymphocytes. Olive leaf contains essential substances like
polyphenols including oleuropein, which increases the release of interferon
lymphocytes. Olive leaf also increases the absolute numbers of the CD8+ and
natural killer cells to improve the defense against viral infections.
Additionally, licorice root with its glycyrrhinic acid, increases the release
of interferon. Licorice root has been used for hundreds of years to fight upper
respiratory viruses.
Zinc
added
for its ability proven in clinical studies to increase the efficacy of
interferon. Zinc is a known trace element that is imperative for the immune
system where it improves the host response to many infections and plays an
important role in the homeostasis of the immune system. In the cases of viral
infection, it increases the interferon efficacy to a multiple as much as
10-fold as well as having direct antiviral activities. Zinc supplementation
decreases the morbidity of lower respiratory tract infections in pediatric
patients in the developing world. In respiratory syncytial virus infections,
for example, zinc prevents the replication of the virus. With rhinoviruses,
zinc appears to inhibit the direct binding of the virus. Zinc also inhibits the
replication of human immunodeficiency virus type I (HIV-1); herpes simplex
virus (HSV); 0020vaccinia virus; and polioviruses.
Elderberry,
Vitamin C, and Lemon Balm added for their ability proven in clinical
studies to inhibit viral replication. One of the important nuclear
transcription factors involved in viral replication in coronavirus infections
is nuclear factor kappa B (NFKappaB). This key transcription factor activates
numerous genes involved in cellular immune response and inflammation. Many
studies have shown that NF-kappa B plays an important role in the pathogenesis
of lung diseases, and therefore, is important to inhibit this nuclear factor in
preventing and/or supporting patients with COVID-19. There are many
antioxidants that inhibit this important factor in viral replication. The most
important ones are Vitamin C, lemon balm and elderberry -- natural substances
that inhibit viral replication through their inhibition of NFKappaB. Additional
mechanisms that fight against viral infections include direct and indirect
immune activation, inhibition of viral replication, and even down regulating
toxic oxygen radicals involved in cell damage from viruses.
Cherry
Extract, Rose Hips and Nicotinamide added for their
ability proven in clinical studies to inhibit the oxygen radicals. The damage
caused by oxygen radicals in viral infections has been known for many years.
The major enzymes involved in this toxicity are xanthine oxidase (XO), NADPH
oxidase and inducible nitric oxide synthase (iNOS). The superoxide radical,
generated from XO and/or NADPH OX combine with the nitric oxide generated from
the iNOS to form the toxic product, peroxynitrite. Viruses, including
coronaviruses, are toxic via this pathway. These radicals are massively
destructive to tissues where they are generated. In the case of COVID-19, this
involves predominantly the lung tissue, causing a decrease in oxygen transfer
leading to major lung toxicity and hypoxia in multiple organs.
The Company has partnered with the
licensor, a Canadian company engaged in the research and development of
proprietary Nutraceutical products, Intellectual properties and other related
formulas for the health and wellness, nutraceutical industries and the general
public, to develop a strategy for brand development, messaging and retail
distribution.
Licensor has granted the Company an
initial exclusive license for the UNITED STATES, GERMANY and COLOMBIA to use
the Licensed Product and the Licensor Intellectual Property to manufacture,
have manufactured and sell the Licensed Product, provided that the Licensed
Product is manufactured in accordance with the specifications and quality
standards submitted or approved by Licensor.
Licensor grants licenses and rights
to the IP Rights and Marks through a base revenue share per unit sold of three
dollars. The Company has also agreed that the licensor will be working in
partnership with the Company to engage a third party or parties at it sole discretion , time and place for
the purpose of marketing, selling and promoting of such licensed products
through major retail chains where in this case that such collaboration will
result in a profit margin sharing.
CEO of Relevium Aurelio Useche
stated, “We are extremely excited to have secured the exclusive license for
this 100% natural synergistic and multi-pathway patented formulation, which we
will be launching in the market over the next months. This is a major addition
to the CleanCare product portfolio adding prevention and immunity support to
the Bioganix line of trusted nutraceuticals”
WeedMD
Inc.
(TSX-V:WMD) (OTCQX:WDDMF) announced that it has entered into an
exclusive licensing, manufacturing and distribution agreement with premium,
U.S.-based cannabis wellness house, MM Technology Holdings, LLC, owner of
Mary’s Brands, and the acclaimed product line, Mary’s Medicinals.
Under the terms of the Agreement, as
Mary’s sole Canadian partner, WeedMD will manufacture a suite of Mary’s
Medicinals’ products in-house with its own input biomass at its
state-of-the-art extraction hub CX Industries later this year. WeedMD will also
market, sell and distribute Mary’s Medicinals’ products across Canada’s
provincial adult-use and direct-to-consumer medical channels as it looks to
expand new cannabis offerings to address an underserved wellness and medical
market segment. Widely recognized for its innovative portfolio of delivery
methods, Mary’s suite of cannabis products includes transdermal gels and
patches and topicals.
“As we move into the next level of
product development, it’s imperative that we strategically partner with
established brands that share our core values and Mary's Brands offers a
superior product line that is backed by a team truly dedicated to ensuring the
quality, integrity and efficacy of its product offerings,” said Angelo
Tsebelis, CEO of WeedMD. “We’re proud to be selected as Mary’s exclusive
Canadian producer and distributor. With our cultivation platform and CX
extraction operations fully ramped-up, there's the added pride of developing
these renowned products in-house as we expand with new cannabis formats into a
lucrative, yet underserved consumer segment.”
“We’re thrilled to be partnering
with WeedMD and its CX extraction team as we execute on our long-term growth
strategy to expand the Mary’s Medicinals brand into Canada,” said Jacques
Panis, CEO of Mary’s Brands. “Our continued desire to innovate on additional
product offerings makes this partnership fitting as we look to collaborate with
a strong, experienced team that brings unparalleled expertise in cultivation
and extraction along with a proven ability to capture unique, next-level
distribution channels.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
Tuesday 4 August 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 449 - Interview with Matt Markiewicz, Managing Director of the Cannabis ETF (NYSE: $THCX)
Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 449 -
Interview with Matt Markiewicz, Managing Director of the Cannabis ETF (NYSE: $THCX)
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/080420-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/08041Interview-Matt-Markiewicz-THCX.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on
Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast Investorideas interviews Matt Markiewicz, the managing director
of The Cannabis ETF (NYSE: THCX), where we discussed some of the
portfolio’s recent earnings reports, how the last few months of COVID-19 have
impacted the ETF as well as expectations moving forward.
Markiewicz
commented on the last few months and how COVID-19 impacted the industry,
specifically focussing on how while the industry remains federally illegal in
the U.S. it was also deemed essential in most states where it is legalized.
“I
think we’ve started to see some optimism come back into the sector and I think
that’s shown through in the stock prices. After hitting that low in mid-March
the ETF is up close to 60% since then, and that’s not uncommon for many of the
other ETF’s. We have seen a nice rebound and we seem to have stabilized here in
that the ETF’s and the stocks seem to be trading sideways a bit. We have also
seen a bit of a decrease in volatility in the sector but it is summer and you
do have less market participants involved and we will still have to see how
things play out into the fall.”
Markiewicz
continued by discussing how this relates to some of the recent earnings
reports.
“In
terms of earnings. This (last week) was one of the first big weeks for Cannabis
earnings reports, we just had Aphria (NASDDAQ: APHA) and Scotts Miracle Gro (NYSE: SMG). The week of August 10th, up in
Canada, Canopy Growth (NYSE:CGC) and Tilray (NASDAQ: TLRY) report and then next week
(this week) we have Cronos and GW Pharmaceutical earnings as well. In the US on
the week of August 10th we get earnings reports from Colombia Care, Harvest,
Acreage, Trulieve and Greenthumb, so that’s going to be a major focus week for
cannabis in general. Who knows we might even have a renewed media focus on
cannabis earnings, which probably should be pretty encouraging based on the
sales levels we’ve seen in the past few months.”
Markiewicz
then went on to discuss in more detail Scotts recent earnings in more depth.
“For
Scotts Miracle Gro most people associate it with golf courses and fertilizer
for your house, but this is a company that is an ancillary play on the growth
of the US cannabis industry and the fact that its listed on the NYSE means that
many investors can buy the issue. It’s been holding in our portfolio since we
launched last July and is the 6th largest holding in the fund, just under 6%.
Scotts reported an absolute blockbuster quarter. Their division, Hawthorne
Gardening, where there are over 40 brands that are leveraged towards the US
cannabis industry which saw sales grow 72% year on year in the third quarter.
Well above what all analysts thought they’d deliver. To me there is also a very
positive readthrough from another company called GrowGeneration Corp. (NASDAQ:GRWG), who is one of the largest US
hydroponics stores, and GrowGeneration sells a lot of the brands that are under
the Hawthorne Gardening banner. So I think it’s an extremely strong readthrough
and a name that investors should keep an eye on. You have to remember that
there aren’t many stocks that have leverage to the US cannabis industry that
can be purchased by US institutional investors. Only about 9% of the publicly
traded cannabis market cap is owned by US institutional investors.”
Markiewicz
went on to discuss some of the other upcoming earnings reports and what market
expectations are so far as well as what investors should be looking for both in
the US and Canada over the next few months.
“After
seeing Organigram’s and Aphria’s earnings I’m not expecting any overly positive
surprises from any of these LP’s yet to report. The narrative at the beginning
of the year was it’s going to be a second half story once we see “2.0” sales
kick in and newer products hitting shelves. Obviously COVID has slowed that
down but the narrative continues to be more optimistic towards the second half
of the year. At what point though is the patience from investors going to wear
thin if that second half story doesn’t materialize. I think it’s very much a
“put up or shut up” time when the third quarter rolls around, for the Canadian
cannabis industry in particular.”
Markiewicz
went on to discuss in more detail some of the expectations for the US industry
over the next few months as well as the ETF’s views on the still very nascent
psychedelic industry.
The
Cannabis ETF was constructed to make investing in cannabis easier by helping investors
get exposure to a basket of stocks that are expected to benefit from growth of
the hemp and legal marijuana industries. To find out more visit their website
at https://thcxetf.com/.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
Friday 31 July 2020
Investorideas.com - House Approves Appropriations Amendment to Protect State-Legal Cannabis Markets
Investorideas.com - House Approves Appropriations Amendment to Protect State-Legal Cannabis Markets
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 448 (CSE: $TER.C) (CSE: $CURA.C) (OTC: $HEMP)
Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 448 (CSE: $TER.C)
(CSE: $CURA.C) (OTC: $HEMP)
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/073120-StocksToWatch.mp3
Read
this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07311TER-CURA-HEMP.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Open
Book Extracts announced its
expansion of operations and distribution channels into Asia, Israel and most
recently, South Africa.
To serve a recently estimated $6.4
billion market opportunity for cannabis in South Africa, OBX was named a
principal distribution partner of Peter Bodill Agencies LTD of South Africa.
With more than 30 years in the agency/distribution business in South Africa,
Peter Bodill Agencies represents manufacturers that specialize in supplying
some of the world’s finest products, such as vitamin mixes, probiotics and
industrial ingredients throughout the entire country. OBX joins global
commercial distribution partner, Prinova Nagase Group, in a short list of
principals vetted and approved by Peter Bodill Agencies for South African
distribution.
“Quality, safety and reliability are
essential in the burgeoning South Africa cannabis market,” stated Peter Bodill,
director of Peter Bodill Agencies LTD. “The caliber of the team and products
from Open Book Extracts has exceeded our expectations. We are excited to be
able to provide its high-quality CBD products, innovative cannabinoid blends
and pure rare cannabinoids to our clients.”
In addition to the South Africa
distribution channel, OBX expanded its footprint into Asia, appointing Laurie
Goldberg as OBX Asia’s chief executive officer. Goldberg, who founded and
recently sold AmeriCraft Imports Limited, a Hong Kong-based craft beer importer
and distributor, will lead expansion efforts into the Asia market.
“With the demand for CBD products in
Asia growing rapidly, it is paramount for leading brands to have a reputable,
quality supplier like Open Book Extracts,” stated Goldberg. “The fact that OBX
is cGMP certified, able to deliver pharma-grade purity levels and is well
versed in global market distribution ensures that we will meet the Asian market
demand for high-quality, safe cannabinoid products.”
“We’re thrilled to expand our
footprint to provide safe and efficacious cannabinoid products worldwide,”
stated Dave Neundorfer, chief executive officer at OBX. “While we are glad to
see countries roll out regulations to permit non-THC cannabinoids in food,
beverages and personal care products, we’re also planning clinical trials for
safety and efficacy to support dietary supplement and pharmaceutical
registrations.”
The establishment of global
distribution channels follows closely on the heels of Open Book Extracts’
recent acquisition of Chilmark Labs and its Israeli affiliate, Beetlebung
Pharma Ltd., enabling the manufacturing of high-purity rare and minor
cannabinoids at commercial scale, and further unlocking the therapeutic
potential of cannabinoid-based products.
TerrAscend
Corp. (CSE:TER) (OTCQX:
TRSSF) today announced that it
has officially opened its seventh retail dispensary location. The new 4,200
square foot Apothecarium dispensary, located at 2312 Telegraph Ave, Berkeley,
CA is the company's fourth California dispensary, and TerrAscend's seventh
dispensary nationwide.
The Apothecarium Berkeley is a
full-service recreational and medical cannabis dispensary featuring a stylish,
upscale design and a staff of highly trained cannabis consultants to assist
guests. The store carries a wide variety of cannabis products, including
edibles, flowers, vaping products, concentrates, capsules, tinctures, topicals,
and ancillary products. The new location offers online ordering at
apothecarium.com for pickup and delivery.
"We are excited to begin
serving our East Bay customers from a beautiful new location on Telegraph
Avenue," said Ryan Hudson, CEO, and co-founder of The Apothecarium.
"At The Apothecarium, our focus is on education. We aim to provide
one-on-one consultations that help our patients and customers find the right
products for their needs. Whether they are looking for help in-person, by phone
or via web chat, our cannabis consultants are here to help."
"For nearly a decade The
Apothecarium has set the standard for dispensary design and customer
service," said Jason Ackerman, CEO of TerrAscend. "The Apothecarium
Berkeley is raising the bar again with a refined look and upgraded technology
that brings the dispensary's famous consultations and cannabis education
classes online. We're delighted to expand our footprint; Berkeley is our fourth
California dispensary and our first in the East Bay."
The Apothecarium Berkeley is
designed to be comfortable and easy to navigate for seniors, first-time
dispensary visitors, and patients with serious medical conditions. The dispensary
features The Apothecarium's typical mix of neo-Victorian furnishings, modern
touches, and plenty of natural light. The store was designed by the same team
behind The Apothecarium's three San Francisco dispensaries: architect Vincent
Gonzaga and the interior design firm, Urban Chalet.
All Apothecarium dispensaries have
implemented strict safety standards to protect guests and team members. Our
California safety protocols include strict social distancing inside and outside
the dispensaries, a mask requirement for everyone inside the dispensaries, no
contact check-in procedures and ongoing sanitizing throughout the day.
Curaleaf
Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF) announced the
launch of Curaleaf Sublingual Tablets in Florida. These cube-shaped,
berry-flavored bites will provide the state's medical patients with a discreet,
sugar-free yet fruity alternative form of medication.
Curaleaf's new Sublingual Tablets,
which will be in 30-piece jars, contain 5mg of high-quality cannabis oil per
piece, which allows patients to manage their treatment plan with confidence and
ease. Each bite, which is made to be ingested orally or sublingually, is
translucent in color and features a refreshing "Arctic Berry" flavor.
The new product will be sold at all of the Company's 28 operating dispensaries
in Florida with a phased roll-out between August 8th - August 20th. Limited
quantities will be released to pre-existing loyalty patients beginning
tomorrow, July 30th. For more information on the product roll-out cadence,
please visit
https://curaleaf.com/blog/curaleaf-sublingual-tablets.
"The demand for alternative
cannabis form functions in Florida has been mounting for years, and we are
thrilled to offer our patients an exciting new product -- Sublingual
Tablets," said Joe Lusardi, Chief Executive Officer at Curaleaf. "Our
success is driven by listening to and meeting the needs of our patients, and we're
incredibly proud to be first to market in Florida with this new option in
cannabis medicine. By providing high-quality products in a variety of
administration routes, we are better positioned to improve our patients' lives,
which has been our mission since day one."
Earlier this summer, Curaleaf began
selling "Shorties," a pre-roll flower product, in response to the
requests of their Florida patients. As an additional offering to the classic 1g
pre-roll, patients can now enjoy freshly harvested flower by way of these
conveniently sized .4g pre-rolls.
Florida's continued growth in
patient registration makes it one of the nation's fastest-growing medical
cannabis markets in the country. Currently, there are over 377,000 medical
patients enrolled in the Florida program - about 1.7% of the state's population
- with approximately 5,000 new patients enrolling each week. To ensure the best
possible service to the increasing number of medical patients, Curaleaf is in
the process of expanding its Florida presence, adding to current grow capacity
and planning to open at least five new dispensaries by Q4.
During the COVID-19 pandemic,
cannabis businesses have been deemed an essential service in most states,
including Florida. Curaleaf remains committed to serving patients and customers
with the products they rely on while implementing heightened safety and
hygienic measures in all its facilities.
Curaleaf's dispensary regular
operating hours remain in effect, and free statewide delivery is always
available for Florida medical patients. Throughout the year, discounts are
offered to senior citizens, military veterans, pediatric patients, and
recipients of government financial assistance. Please visit
www.curaleaf.com/locations to find a dispensary near you.
Geocann announced that
the company has commercialized the first oral dose application that overcomes
the well-known bioavailability challenges of science-backed, key ingredients
found in popular immunity support products. The multi-patented VESIsorb®
delivery system provides the much-needed solution that turns the following
poorly absorbed individual compounds into a synergistic, 4-in-1 formulation
with dramatic improvements in absorption and bioavailability:
● 50 mg
curcumin from turmeric root;
●
15 mg cannabidiol (CBD) from broad spectrum
hemp extract;
●
7 mg beta-caryophyllene (BCP) that has
received FDA GRAS status; and
● 200 IU
vitamin D3.
“These
ingredients have been strategically selected for their immunity support and
anti-inflammatory properties, but are notorious for showing limited
bioavailability due to their lipophilicity and extensive first-pass
metabolism,” said Anthony Petraglia, M.D., Chief Medical Officer. “With a
successful track record over the past fifteen years, VESIsorb® has
consistently demonstrated its ability to mitigate these negative effects while
significantly improving the pharmacokinetic performance of natural ingredients.
To put it simply, bioavailability is the key to providing an immunity support
product that delivers its desired health benefits.”
This
formulation milestone comes on the heels of a study that was published in the
peer-reviewed journal, Molecules,
showcasing the numerous advantages of broad spectrum hemp extract formulated
with VESIsorb® to that of the same broad spectrum hemp extract
combined with medium chain triglycerides (MCT) oil. Key findings included that
an important subgroup showed statistically significant improvements for all
measured pharmacokinetic parameters, including a 712% increase in maximal
plasma CBD concentration (Cmax), a 449% improvement in total CBD exposure over
time [area under the curve (AUC)], and a 400% improvement in time to peak
absorption (Tmax).
“Geocann
has a strategic focus to deliver cannabinoid and terpene products with an
unmatched body of supporting scientific evidence that address the most pressing
health concerns,” said Sam Davidson, Chief Operating Officer. “The marketplace
demand for natural immunity support products is unprecedented, and the
relationship between a healthy immune system and a strong endocannabinoid
system (ECS) is well-documented. More than ever, we are committed to pioneering
these innovative solutions with our technical formulation expertise, rigorous
product development protocol, and global distribution infrastructure.”
Geocann
has the exclusive global rights to the patented VESIsorb® drug delivery
technology for cannabinoids, terpenes, and flavonoid formulations. The company
is strategically partnering with leading lifestyle brands that share a
commitment to superior product safety, quality, and performance. The VESIsorb®
drug delivery system has been successfully applied to a wide range of cannabis
based product applications, including soft gel and hard shell capsules,
functional foods (e.g. gummies) and beverages, powder systems, tinctures,
sublingual sprays, and topically applied formulations.
Hemp,
Inc. (OTC:
HEMP) commended
Congress for approving an amendment to the National Defense Authorization Act
(NDAA) permitting military service members to use CBD and hemp-derived
products.
The amendment supersedes months of
confusion surrounding cannabidiol (CBD) policy earlier this year and addresses
policies across military organizations following the legalization of hemp in
the 2018 Farm Bill. The amendment also includes a measure allowing heads of
military branches to issue reenlistment waivers to members of the armed forces
who admit to using cannabis.
The approved measure is also
celebrated by Hemp Inc.’s strategic hemp growing partner Veterans Village Kins Community in Arizona which is designed to
grow hemp for CBD products that benefit veterans, generate revenues for the
residents, and to support the holistic healing and learning center at the heart
of the community.
“This is a step in the right
direction for cannabis policy reform provisions and we’re very pleased that
Congress has taken the initiative to allow military members to utilize the
natural benefits of hemp to remedy the mental and physical effects of serving
our country,” said Hemp, Inc. CEO Bruce Perlowin. “Working with our veteran
partners at Veteran Village Kins Community in Arizona, Inc. we can see the good
that CBD has on former military service members and this only illustrates the
therapeutic and preventative effects it can have on active members as well.”
According to the Department of
Defense Suicide Prevention (DoDSER) 2017 annual report, there were 1,397
non-fatal suicide attempts by active-duty service members. However, a 2015
study titled ‘Cannabidiol as a Potential Treatment for Anxiety Disorders’
showed CBD usage to be most effective in helping people deal with traumatic
events within an hour of the experience, suggesting that using CBD while on
active duty could probably decrease the development of PTSD and severe anxiety
before it is too late.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
Subscribe to:
Posts (Atom)
-
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...